Drug Approval | December 26, 2023
Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment
US FDA approval based on NEURO-TTRansform Phase III results
US FDA approval based on NEURO-TTRansform Phase III results
The state-of-the-art digital PETCT imaging system, highlights a significant advancement in the fight against cancer and detects other lesions offering patient centric services
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
To equip them with the latest knowledge and skills to handle patients coming to them in a better way
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
The partnership will capitalize on the combined capabilities of the two organizations
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Several late-stage pipeline products have the potential to address some of these unmet needs
Women of all ages will get round-the-clock access to comprehensive treatment
Subscribe To Our Newsletter & Stay Updated
